Pain Treatments

Almost 20 per cent of the European population suffers from chronic pain, which is a major burden for both the persons concerned and their families.1

In order to relieve the pain, analgesic medications are typically used. The more severe the pain, the stronger the analgesic used, i.e. the further up the World Health Organisation (WHO) ladder. Grünenthal is specialised in pain therapy and is constantly searching for new ways to improve the quality of life of sufferers by providing effective and reliable analgesics. Grünenthal’s portfolio covers a variety of treatment options for both chronic and acute pain conditions. The products are available in more than 100 countries, most of them as prescription medicines.

In this section you will find information on our product portfolio:

  • Palexia®
  • Qutenza®
  • Vimovo®
  • Nexium®
  • Versatis®
  • Zomig®
  • Ixprim®
  • Zydol®


1 Breivik H et al.: Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment. European Journal of Pain, 2006; 10: 287-333

Contact for Medical Information, Reporting Safety and Quality Related Issues:

If you need more information about our products please contact us via the email address or our Medical Information Direct Line below:


Phone: + 44 870 351 8960
Fax: + 44 1494 486 298

M-ALL-IE-05-19-0001 Date of Preparation: May 2019